scholarly journals Primary Dural Lymphoma Mimicking En Plaque Cerebellopontine Angle Meningioma

2021 ◽  
Vol 2021 ◽  
pp. 1-3
Author(s):  
Mei Xu ◽  
Ashish Bains ◽  
Yuan Rong
Keyword(s):  
Primary Cns Lymphoma ◽  
Residual Tumor ◽  
Good Prognosis ◽  
Primary Diagnosis ◽  
Brain Parenchyma ◽  
Cns Lymphoma ◽  
Low Grade ◽  
Postoperative Radiation Therapy ◽  
Systemic Involvement ◽  
Dural Lymphoma

Primary dural lymphoma (PDL) usually arises from the calvarial dura without the brain parenchyma or systemic involvement and thus may not be considered as a typical form of primary CNS lymphoma (PCNSL). It is exceedingly rare. When it occurs, it might not be suspected as a primary diagnosis on clinical and radiologic findings. We present a PDL case that occurs at the cerebellopontine (CP) angle mimicking en plaque meningioma. The tumor histopathology showed a lymphoproliferative disorder immunophenotypically consistent with a low-grade marginal zone lymphoma. Bone marrow and systemic involvements were not identified, and a diagnosis of PDL was established. As a residual tumor at the CP angle was inaccessible to surgery, postoperative radiation therapy was performed. No recurrence was found at 15-month follow-up. PDLs are mostly indolent and have a good prognosis. There is no doubt that the most important differential diagnosis is meningioma. Furthermore, the present case emphasizes the necessity of an intraoperative consultation and knowledge of this rare yet essential form of PCNSL so that appropriate studies can be ordered.

scholarly journals Hemorrhagic Lacrimation and Epistaxis in Acute Hemorrhagic Edema of Infancy

2016 ◽  
Vol 2016 ◽  
pp. 1-3 ◽  
Author(s):  
Shireen Mreish ◽  
Hossam Al-Tatari
Keyword(s):  
Good Prognosis ◽  
Cutaneous Vasculitis ◽  
Low Grade ◽  
Peripheral Edema ◽  
Systemic Involvement ◽  
Classic Triad

Acute hemorrhagic edema of infancy is an uncommon benign cutaneous vasculitis. Despite its worrisome presentation, it carries good prognosis with rarely reported systemic involvement. Management of these cases has been an area of debate with majority of physicians adopting conservative modalities. We report a case that presented with classic triad of rash, low grade fever, and peripheral edema along with two rarely reported manifestations in literature: hemorrhagic lacrimation and epistaxis.

Clinicopathologic and Genetic Profile of Intracranial Marginal Zone Lymphoma: A Primary Low-Grade CNS Lymphoma That Mimics Meningioma

2005 ◽  
Vol 23 (24) ◽  
pp. 5718-5727 ◽  
Author(s):  
Pang-hsien Tu ◽  
Caterina Giannini ◽  
Alexander R. Judkins ◽  
Jason M. Schwalb ◽  
Richard Burack ◽  
...  
Keyword(s):  
Marginal Zone ◽  
Primary Cns Lymphoma ◽  
B Cell Lymphoma ◽  
Cns Lymphoma ◽  
Genetic Profile ◽  
Low Grade ◽  
Barr Virus ◽  
Genetic Features ◽  
Trisomy 3 ◽  
Epstein Barr

Purpose Although rare overall, marginal zone B-cell lymphoma (MZBCL) is the most common primary low-grade CNS lymphoma reported in the literature. The aim of this study is to elucidate the biology and genetic features of this unusual tumor. Patients and Methods Fifteen CNS MZBCLs were studied clinically, pathologically, and genetically, including fluorescent in situ hybridization analyses with commercially available MALT1 and IgH break-apart and centromere 3, 7, 12, and 18 probes. Results CNS MZBCLs preferentially affect middle-aged women (female-to-male ratio, 4:1), with 93% presenting as dural-based masses mimicking meningioma. Ten patients with 1 to 7.6 years of follow-up after diagnosis showed no evidence of disease after radiation and/or chemotherapy. Like MZBCLs outside of the CNS, they consisted of CD20+, CD3− small B lymphocytes with varying degrees of plasmacytic differentiation and predominantly κ light-chain restriction (78%). Lymphoid follicles with follicular colonization were seen in three patients and deposition of amyloid was noted in samples from two patients, one of which was tumefactive. Neither Bcl-6 protein nor Epstein-Barr virus–encoded RNA was expressed. Trisomy 3 was detected in six of 12 patients, with no rearrangements of MALT1 or IgH and no trisomies of 7, 12, or 18 detected. Conclusion Our data suggest that intracranial MZBCL is an indolent primary CNS lymphoma that typically presents as a meningioma-like dural-based mass. Trisomy 3, but not MALT1 or IgH translocation, is a common genetic abnormality that may contribute to the pathogenesis of this CNS lymphoma.

Characteristics and outcomes of elderly patients with primary CNS lymphoma (PCNSL)

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. 2070-2070
Author(s):  
D. E. Ney ◽  
A. S. Reiner ◽  
H. D. Skinner ◽  
K. S. Panageas ◽  
L. M. DeAngelis ◽  
...  
Keyword(s):  
Elderly Patients ◽  
Salvage Therapy ◽  
Primary Cns Lymphoma ◽  
Initial Therapy ◽  
Cns Lymphoma ◽  
Small Subset ◽  
High Dose ◽  
Chemotherapeutic Regimen ◽  
Systemic Involvement ◽  
Entire Cohort

2070 Background: The incidence of PCNSL is increasing and is highest in those ≥ 65 years of age. Systemic chemotherapy (CT) ± radiotherapy (RT) improves survival, but treatment related toxicity is greatest in this population. The optimal treatment has yet to be determined. The aim of this study was to characterize older patients with PCNSL at our institution and identify outcomes related to treatment. Methods: We identified patients ≥ 65 years of age treated for PCNSL from 1986 to 2008. Charts were reviewed for demographics, treatment details, tumor progression, and survival. Approval for this study was obtained from the IRB at MSKCC. Results: 174 patients were identified with a median age of 72 years (range: 65–89). 60% of patients had a stereotactic biopsy for diagnosis; 93% had a histologic or cytologic diagnosis. 14 patients had evidence of systemic involvement with detailed staging evaluation. 82% of patients received a high-dose methotrexate (3.5g/m2) regimen, only 13% did not receive CT. Among the patients who received CT, 76% had a radiographic response (CR+PR), 3% had stable disease while 12% progressed. Only 26% had RT as part of initial therapy. CR rate to initial therapy was 67%, 52% of these patients eventually relapsed. Median time to progression was 24 months (range: 1–91). Among the patients who relapsed, 85% received salvage therapy consisting of CT (n = 42), RT (n = 14), or both (n = 7) while 15% received no further treatment. 48% of patients had a CR or PR to salvage therapy while 26% had PD; the remainder were not evaluated. Median overall survival for the entire cohort was 25 months (range: 0.5 to 177+) with a 3-year survival of 36%. 17% developed late treatment-related neurologic toxicity. Administration of RT was associated with the development of neurotoxicity (p < 0.0001). 39 patients remain alive with a median follow-up of 34 months (range: 0.5–177). Conclusions: Elderly patients can receive an aggressive chemotherapeutic regimen with good outcomes. Systemic staging is also valuable as a small subset of patients will have systemic involvement at diagnosis. Clinical trials to optimize treatments for this population are critical. No significant financial relationships to disclose.

First-line temozolomide therapy and MGMT status in elderly patients with primary CNS lymphoma

2009 ◽  
Vol 36 (S 02) ◽  
Author(s):  
M Glas ◽  
D Kurzwelly ◽  
P Roth ◽  
K Rasch ◽  
E Weimann ◽  
...  
Keyword(s):  
Elderly Patients ◽  
Primary Cns Lymphoma ◽  
Cns Lymphoma ◽  
First Line

Combination of microsurgery and Gamma Knife surgery for the treatment of intracranial chondrosarcomas

2006 ◽  
Vol 105 (Supplement) ◽  
pp. 18-25 ◽  
Author(s):  
Petter Förander ◽  
Tiit Rähn ◽  
Lars Kihlström ◽  
Elfar Ulfarsson ◽  
Tiit Mathiesen
Keyword(s):  
Gamma Knife ◽  
Cranial Nerve ◽  
Residual Tumor ◽  
Local Tumor Control ◽  
Gamma Knife Surgery ◽  
Long Term Results ◽  
Tumor Control ◽  
Low Grade ◽  
Cranial Nerve Palsies ◽  
Tumor Volume Reduction

ObjectIntracranial chondrosarcomas have a high risk of recurrence after surgery. This retrospective study of patients with intracranial chondrosarcoma was conducted to determine the long-term results of microsurgery followed by Gamma Knife surgery (GKS) for residual tumor or recurrence.MethodsThe authors treated nine patients whose median age was 36 years. Seven patients had low-grade chondrosarcomas (LGCSs), whereas mesenchymal chondrosarcomas (MCSs) were diagnosed in two. Radiosurgery was performed in eight patients, whereas one patient declined further surgical intervention and tumor-volume reduction necessary for the GKS.The patients were followed up for 15 to 173 months (median 108 months) after diagnosis and 3 to 166 months (median 88 months) after GKS. Seven patients had residual tumor tissue after microsurgery, and two operations appeared radical. In the two latter cases, tumors recurred after 25 and 45 months. Thus, definite tumor control was not achieved after surgery alone in any patient, whereas the addition of radiosurgery allowed tumor control in all six patients with LGCSs. Two of these patients experienced an initial tumor regrowth after GKS; in both cases the recurrences were outside the prescribed radiation field. The patients underwent repeated GKS, and subsequent tumor control was observed. An MCS was diagnosed in the remaining two patients. Complications after microsurgery included diplopia, facial numbness, and paresis. After GKS, one patient had radiation necrosis, which required microsurgery, and two patients had new cranial nerve palsies.Conclusions Tumor control after microsurgery alone was not achieved in any patient, whereas adjuvant radiosurgery provided local tumor control in six of eight GKS-treated patients. Tumor control was not achieved in the two patients with MCS. Similar to other treatments for intracranial chondrosarcoma, morbidity after micro- and radiosurgical combination therapy was high and included severe cranial nerve palsies.

Sign in / Sign up

Export Citation Format

Share Document